Pobilukast

Pobilukast is a leukotriene receptor antagonist (LTRA) that is primarily used in the management of asthma and allergic rhinitis. It functions by blocking the action of leukotrienes, which are inflammatory chemicals the body releases after coming in contact with an allergen or irritant. By inhibiting these chemicals, Pobilukast helps to reduce inflammation, bronchoconstriction, and mucus production in the airways.

Mechanism of Action

Pobilukast works by selectively binding to the cysteinyl leukotriene receptor type 1 (CysLT1) in the lungs and bronchial tubes. This prevents leukotrienes from attaching to these receptors, thereby inhibiting their ability to cause inflammation and constriction of the airways. Leukotrienes are known to play a significant role in the pathophysiology of asthma and allergic rhinitis, making Pobilukast an effective treatment option for these conditions.

Pharmacokinetics

Pobilukast is administered orally and is well absorbed from the gastrointestinal tract. It has a high bioavailability and is extensively metabolized in the liver. The drug is primarily excreted in the urine, with a half-life that allows for once-daily dosing. The pharmacokinetic profile of Pobilukast supports its use as a long-term management option for chronic conditions like asthma.

Clinical Uses

Pobilukast is indicated for the prophylaxis and chronic treatment of asthma in adults and children. It is also used to relieve symptoms of allergic rhinitis, such as sneezing, runny nose, and nasal congestion. Pobilukast is not intended for the relief of acute asthma attacks, and patients are advised to have a rescue inhaler available for such situations.

Side Effects

Common side effects of Pobilukast include headache, dizziness, and gastrointestinal disturbances such as nausea and diarrhea. Rarely, it may cause liver enzyme abnormalities, and patients are advised to report any signs of liver dysfunction, such as jaundice or dark urine, to their healthcare provider.

Contraindications

Pobilukast is contraindicated in patients with known hypersensitivity to the drug or any of its components. Caution is advised in patients with hepatic impairment, as the drug is metabolized in the liver.

Drug Interactions

Pobilukast may interact with other medications that are metabolized by the liver, such as certain anticonvulsants and antibiotics. It is important for healthcare providers to review a patient's medication history to avoid potential interactions.

Also see

• Leukotriene receptor antagonist
• Asthma
• Allergic rhinitis
• Montelukast
• Zafirlukast